8-K: Corcept's Relacorilant Faces FDA Setback for Hypertension

Corcept Therapeutics received a Complete Response Letter from the FDA for relacorilant as a treatment for hypertension secondary to hypercortisolism, citing a need for additional effectiveness evidence.

Summary

• The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
• The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the company's GRADIENT trial provided confirmatory evidence.
• The Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.
• Corcept's CEO, Joseph K. Belanoff, expressed surprise and disappointment, stating the company's commitment to patients and plans to meet with the FDA to discuss the path forward.
• Relacorilant is also being developed for platinum-resistant ovarian cancer, with a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026, and a Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA).
• Corcept's existing medication, Korlym, was approved in February 2012 for the treatment of patients with endogenous hypercortisolism.

Sentiment

Score: 3

Explanation: The FDA's Complete Response Letter for relacorilant for a key indication is a major setback, introducing significant regulatory uncertainty and delaying potential market entry for this use. While other indications are progressing, this specific rejection is a material negative event.

Positives

• The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint for relacorilant.
• Data from the GRADIENT trial provided confirmatory evidence for relacorilant.
• Relacorilant has been designated an orphan drug by the FDA and the European Commission (EC) for hypercortisolism and by the EC for ovarian cancer.
• Relacorilant has a PDUFA date of July 11, 2026, for platinum-resistant ovarian cancer, indicating ongoing progress in other indications.
• Corcept has an existing approved medication, Korlym, for endogenous hypercortisolism, demonstrating a track record in the field.

Negatives

• The FDA issued a Complete Response Letter (CRL) for relacorilant for hypertension secondary to hypercortisolism.
• The FDA concluded it could not arrive at a favorable benefit-risk assessment without additional evidence of effectiveness for this indication.
• This outcome will delay or potentially prevent the approval of relacorilant for hypertension secondary to hypercortisolism.

Risks

• Regulatory risk associated with the FDA's Complete Response Letter for relacorilant, requiring additional evidence of effectiveness.
• Uncertainty regarding the timeline and requirements for resubmission or further clinical trials for relacorilant in hypertension secondary to hypercortisolism.
• Potential impact on the company's financial performance and stock price due to the delay or non-approval of relacorilant for this indication.
• Reliance on future regulatory approvals for other indications of relacorilant, such as platinum-resistant ovarian cancer.

Future Outlook

Management plans to meet with the FDA as soon as possible to discuss the best path forward for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. The company continues to develop relacorilant for other serious disorders, including platinum-resistant ovarian cancer, with a PDUFA date set for July 11, 2026, and an MAA submitted to the EMA for this indication. Corcept is also conducting advanced clinical trials for solid tumors, ALS, and liver disease.

Management Comments

• "We are surprised and disappointed by this outcome."
• "Our commitment to patients suffering from the effects of hypercortisolism is unwavering."
• "I am confident we will find a way to get relacorilant to the patients it could help."
• "We will meet with the FDA as soon as possible to discuss the best path forward."

Industry Context

The pharmaceutical industry is characterized by high regulatory hurdles and significant R&D investment. FDA Complete Response Letters are a common occurrence, indicating that the agency requires more data or addresses specific deficiencies before approving a New Drug Application. This event highlights the inherent regulatory risks in drug development, even for drugs that have met primary endpoints in clinical trials, and can significantly impact a company's stock performance and future pipeline strategy.

Stakeholder Impact

• Shareholders may experience a negative impact on stock value due to the regulatory setback and increased uncertainty surrounding relacorilant's approval for hypertension secondary to hypercortisolism.
• Patients suffering from hypertension secondary to hypercortisolism will face delays in accessing relacorilant as a potential treatment.
• Employees may experience uncertainty regarding the future development and commercialization of relacorilant for this specific indication.

Next Steps

• Meet with the FDA as soon as possible to discuss the best path forward for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
• Continue development of relacorilant for platinum-resistant ovarian cancer, with a PDUFA date of July 11, 2026.
• Pursue the Marketing Authorization Application (MAA) for relacorilant to treat patients with platinum-resistant ovarian cancer with the European Medicines Agency (EMA).
• Continue advanced clinical trials for relacorilant in patients with solid tumors, ALS, and liver disease.

Key Dates

Recommendation

The FDA's Complete Response Letter for relacorilant for hypertension secondary to hypercortisolism represents a significant regulatory setback and introduces substantial uncertainty regarding the drug's approval for this indication. While other indications are in development, this rejection for a primary use case is a material negative event that is likely to impact investor confidence and the company's near-term prospects, warranting a 'sell' recommendation.

Keywords

Corcept Therapeutics, CORT, Relacorilant, FDA, Complete Response Letter, CRL, Hypercortisolism, Hypertension, Drug Development, Pharmaceuticals, Orphan Drug, NDA, Clinical Trials